Susan Mason

Susan Mason

Auto-generated profile, based on publicly available information

Susan Mason

The CRUK Beatson Institute

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2012 in Nature
Verified
Journal Article
Closed access
PDF file
OMOliver D. K. Maddocks
Oliver D. K. Maddocks
CBCelia R. Berkers
Celia R. Berkers
SMSusan M. Mason
Susan M. Mason
LZLiang Zheng
Liang Zheng
KBKaren Blyth
Karen Blyth
KVKaren H. Vousden
Karen H. Vousden

1 January 2015 in Cancer Cell
Verified
Journal Article
Open access
ZSZachary Schug
Zachary Schug
Barrie PeckBarrie Peck
Barrie Peck
DJDylan T. Jones
Dylan T. Jones
QZQifeng Zhang
Qifeng Zhang
SGShaun Grosskurth
Shaun Grosskurth
EGEyal Gottlieb
Eyal Gottlieb
A functional genomics study revealed that the activity of acetyl-CoA synthetase 2 (ACSS2) contributes to cancer cell growth under low-oxygen and lipid-depleted conditions. Comparative metabolomics and lipidomics demonstrated that acetate is used as a nutritional source by cancer cells in an ACSS2-dependent manner, and supplied a significant fraction of the carbon within the fatty acid and phospholipid pools. ACSS2 expression is upregulated under metabolically stressed conditions and ACSS2 silencing reduced the growth of tumor xenografts. ACSS2 exhibits copy-number gain in human breast tumors, and ACSS2 expression correlates with disease progression. These results signify a critical role for acetate consumption in the production of lipid biomass within the harsh tumor microenvironment.

1 March 2015 in Molecular Cell
Verified
Journal Article
Open access
GIGabriel Ichim
Gabriel Ichim
JLJonathan Lopez
Jonathan Lopez
SAShafiq U. Ahmed
Shafiq U. Ahmed
NMNathiya Muthalagu
Nathiya Muthalagu
EGEvangelos Giampazolias
Evangelos Giampazolias
STStephen W.G. Tait
Stephen W.G. Tait
During apoptosis, the mitochondrial outer membrane is permeabilized, leading to the release of cytochrome c that activates downstream caspases. Mitochondrial outer membrane permeabilization (MOMP) has historically been thought to occur synchronously and completely throughout a cell, leading to rapid caspase activation and apoptosis. Using a new imaging approach, we demonstrate that MOMP is not an all-or-nothing event. Rather, we find that a minority of mitochondria can undergo MOMP in a stress-regulated manner, a phenomenon we term "minority MOMP." Crucially, minority MOMP leads to limited caspase activation, which is insufficient to trigger cell death. Instead, this caspase activity leads to DNA damage that, in turn, promotes genomic instability, cellular transformation, and tumorigenesis. Our data demonstrate that, in contrast to its well-established tumor suppressor function, apoptosis also has oncogenic potential that is regulated by the extent of MOMP. These findings have important implications for oncogenesis following either physiological or therapeutic engagement of apoptosis.

13 October 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
JWJosephine Walton
Josephine Walton
JBJulianna Blagih
Julianna Blagih
DEDarren Ennis
Darren Ennis
ELElaine Leung
Elaine Leung
SDSuzanne Dowson
Suzanne Dowson
IMIain McNeish
Iain McNeish
There is a need for transplantable murine models of ovarian high-grade serous carcinoma (HGSC) with regard to mutations in the human disease to assist investigations of the relationships between tumor genotype, chemotherapy response, and immune microenvironment. In addressing this need, we performed whole-exome sequencing of ID8, the most widely used transplantable model of ovarian cancer, covering 194,000 exomes at a mean depth of 400× with 90% exons sequenced >50×. We found no functional mutations in genes characteristic of HGSC (Trp53, Brca1, Brca2, Nf1, and Rb1), and p53 remained transcriptionally active. Homologous recombination in ID8 remained intact in functional assays. Further, we found no mutations typical of clear cell carcinoma (Arid1a, Pik3ca), low-grade serous carcinoma (Braf), endometrioid (Ctnnb1), or mucinous (Kras) carcinomas. Using CRISPR/Cas9 gene editing, we modeled HGSC by generating novel ID8 derivatives that harbored single (Trp53–/–) or double (Trp53–/–;Brca2–/–) suppressor gene deletions. In these mutants, loss of p53 alone was sufficient to increase the growth rate of orthotopic tumors with significant effects observed on the immune microenvironment. Specifically, p53 loss increased expression of the myeloid attractant CCL2 and promoted the infiltration of immunosuppressive myeloid cell populations into primary tumors and their ascites. In Trp53–/–;Brca2–/– mutant cells, we documented a relative increase in sensitivity to the PARP inhibitor rucaparib and slower orthotopic tumor growth compared with Trp53–/– cells, with an appearance of intratumoral tertiary lymphoid structures rich in CD3+ T cells. This work validates new CRISPR-generated models of HGSC to investigate its biology and promote mechanism-based therapeutics discovery. Cancer Res; 76(20); 6118–29. ©2016 AACR.

1 April 2016 in Cancer & Metabolism
Verified
Journal Article
Open access
PDF file
Barrie PeckBarrie Peck
Barrie Peck
ZSZachary T. Schug
Zachary T. Schug
QZQifeng Zhang
Qifeng Zhang
BDBeatrice Dankworth
Beatrice Dankworth
DJDylan T. Jones
Dylan T. Jones
ASAlmut SChulze
Almut SChulze
Enhanced macromolecule biosynthesis is integral to growth and proliferation of cancer cells. Lipid biosynthesis has been predicted to be an essential process in cancer cells. However, it is unclear which enzymes within this pathway offer the best selectivity for cancer cells and could be suitable therapeutic targets. Using functional genomics, we identified stearoyl-CoA desaturase (SCD), an enzyme that controls synthesis of unsaturated fatty acids, as essential in breast and prostate cancer cells. SCD inhibition altered cellular lipid composition and impeded cell viability in the absence of exogenous lipids. SCD inhibition also altered cardiolipin composition, leading to the release of cytochrome C and induction of apoptosis. Furthermore, SCD was required for the generation of poly-unsaturated lipids in cancer cells grown in spheroid cultures, which resemble those found in tumour tissue. We also found that SCD mRNA and protein expression is elevated in human breast cancers and predicts poor survival in high-grade tumours. Finally, silencing of SCD in prostate orthografts efficiently blocked tumour growth and significantly increased animal survival. Our data implicate lipid desaturation as an essential process for cancer cell survival and suggest that targeting SCD could efficiently limit tumour expansion, especially under the metabolically compromised conditions of the tumour microenvironment.

16 January 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
KCKirsteen Campbell
Kirsteen Campbell
SDSandeep Dhayade
Sandeep Dhayade
NFNicola Ferrari
Nicola Ferrari
ASAndrew H Sims
Andrew H Sims
EJEmma Johnson
Emma Johnson
KBKaren Blyth
Karen Blyth
Analysis of publicly available genomic and gene expression data demonstrates that MCL1 expression is frequently elevated in breast cancer. Distinct from other pro-survival Bcl-2 family members, the short half-life of MCL-1 protein led us to investigate MCL-1 protein expression in a breast cancer tissue microarray and correlate this with clinical data. Here, we report associations between high MCL-1 and poor prognosis in specific subtypes of breast cancer including triple-negative breast cancer, an aggressive form that lacks targeted treatment options. Deletion of MCL-1 in the mammary epithelium of genetically engineered mice revealed an absolute requirement for MCL-1 in breast tumorigenesis. The clinical applicability of these findings was tested through a combination of approaches including knock-down or inhibition of MCL-1 to show triple-negative breast cancer cell line dependence on MCL-1 in vitro and in vivo. Our data demonstrate that high MCL-1 protein expression is associated with poor outcome in breast cancer and support the therapeutic targeting of MCL-1 in this disease.